Paxlovid efficacy ‘not established’ for low-risk patients: study
Professor Allen Cheng says the findings support current use of antivirals in high-risk individuals
Nirmatrelvir-ritonavir is no better than placebo for resolving symptoms in patients who are at low risk for severe COVID-19, results from an international study suggest.
The phase II/III trial showed no significant difference between nirmatrelvir-ritonavir (Paxlovid) and placebo for time to symptom alleviation in patients with confirmed COVID-19.
“The usefulness of nirmatrelvir-ritonavir in patients who are not at high risk for severe COVID-19 has not been established,” the investigators concluded.
Infectious disease physician Professor Allen Cheng, who was not involved in the study, told AusDoc this finding “isn’t that surprising”.
